Publications

Selected publications from Center for Hematology and Regenerative Medicine (HERM)

Hong Qian 

Molecular characterization of prospectively isolated multipotent mesenchymal progenitors provides new insight into the cellular identity of mesenchymal stem cells in mouse bone marrow.
Qian H, Badaloni A, Chiara F, Stjernberg J, Polisetti N, Nihlberg K, et al
Mol. Cell. Biol. 2013 Feb;33(4):661-77   

A novel Lin-CD34+CD38- integrin α2- bipotential megakaryocyte-erythrocyte progenitor population in the human bone marrow.
Wong W, Dolinska M, Sigvardsson M, Ekblom M, Qian H
Leukemia 2016 Jun;30(6):1399-402   

Sören Lehmann

Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia.
Qu Y, Siggens L, Cordeddu L, Gaidzik V, Karlsson K, Bullinger L, et al
Blood 2017 02;129(7):e13-e25

Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013.
Lehmann S, Deneberg S, Antunovic P, Rangert-Derolf , Garelius H, Lazarevic V, et al
Leukemia 2017 Jun;31(6):1457-1459

Petter Höglund

Platelets made HLA deficient by acid treatment aggregate normally and escape destruction by complement and phagocytes in the presence of HLA antibodies.
Meinke S, Sandgren P, Mörtberg A, Karlström C, Kadri N, Wikman A, et al
Transfusion 2016 Feb;56(2):370-82; quiz 369

Independent control of natural killer cell responsiveness and homeostasis at steady-state by CD11c+ dendritic cells.
Luu T, Ganesan S, Wagner A, Sarhan D, Meinke S, Garbi N, et al
Sci Rep 2016 Dec;6():37996

Julian Walfridsson

JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells.
Pasini D, Cloos P, Walfridsson J, Olsson L, Bukowski J, Johansen J, et al
Nature 2010 Mar;464(7286):306-10

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Herold N, Rudd S, Ljungblad L, Sanjiv K, Myrberg I, Paulin C, et al
Nat. Med. 2017 Feb;23(2):256-263

Evren Alici

Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach.
Alici E, Chrobok M, Lund J, Ahmadi T, Khan I, Duru A, et al
Br. J. Haematol. 2016 Aug;174(3):473-7

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma.
Duru A, Sutlu T, Wallblom A, Uttervall K, Lund J, Stellan B, et al
PLoS ONE 2015 ;10(9):e0138248

Mattias Carlsten

Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma.
Carlsten M, Korde N, Kotecha R, Reger R, Bor S, Kazandjian D, et al
Clin. Cancer Res. 2016 Nov;22(21):5211-5222

Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.
Childs R, Carlsten M
Nat Rev Drug Discov 2015 Jul;14(7):487-98

Hareth Nahi

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
Usmani S, Weiss B, Plesner T, Bahlis N, Belch A, Lonial S, et al
Blood 2016 07;128(1):37-44

Changes in spatial tuning of the pattern electroretinogram with age.
Porciatti V, Falsini B, Fadda A, Neroni M, Minnella A, Scalia G
Metab Pediatr Syst Ophthalmol (1985) 1989 ;12(1-3):74-5

Petter Woll

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.
Woll P, Kjällquist U, Chowdhury O, Doolittle H, Wedge D, Thongjuea S, et al
Cancer Cell 2014 Jun;25(6):794-808

Persistent malignant stem cells in del(5q) myelodysplasia in remission.
Tehranchi R, Woll P, Anderson K, Buza-Vidas N, Mizukami T, Mead A, et al
N. Engl. J. Med. 2010 Sep;363(11):1025-37

Johanna Ungerstedt

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.
Tobiasson M, Abdulkadir H, Lennartsson A, Katayama S, Marabita F, De Paepe A, et al
Oncotarget 2017 Apr;8(17):28812-28825

Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Lyberg K, Ali H, Grootens J, Kjellander M, Tirfing M, Arock M, et al
Oncotarget 2017 Feb;8(6):9647-9659

Eva Hellström Lindberg

Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality.
Dimitriou M, Woll P, Mortera-Blanco T, Karimi M, Wedge D, Doolittle H, et al
Oncotarget 2016 Nov;7(45):72685-72698

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.
Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M, Jansson M, et al
Blood 2015 Jul;126(2):233-41

Yenan Bryceson

Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function.
Schlums H, Cichocki F, Tesi B, Theorell J, Beziat V, Holmes T, et al
Immunity 2015 Mar;42(3):443-56

Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms.
Tesi B, Davidsson J, Voss M, Rahikkala E, Holmes T, Chiang S, et al
Blood 2017 04;129(16):2266-2279

Sten Eirik Jacobsen

Giustacchini A*, Thongjuea S*, Barkas N, Woll PS, Sopp P, Norfo R, Rodriguez Meira A, Booth C, Ashley N, Jamieson L, Anderson K, Segerstolpe A, Qian H, Stromberg U, Mustjoki S, Sandberg R, Jacobsen SE*, Mead AJ*. Single-cell transcriptomics uncovers distinct and clinically predictive molecular signatures of stem cell in chronic myeloid leukemia. Nature Medicine, In press (*Equal contribution).

Initial seeding of the embryonic thymus by immune-restricted lympho-myeloid progenitors.
Luis T, Luc S, Mizukami T, Boukarabila H, Thongjuea S, Woll P, et al
Nat. Immunol. 2016 Dec;17(12):1424-1435

Publication